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Strongyloidasis is a neglected tropical disease caused by
Strongyloides stercoralis, which affects >100 million people, largely
in Africa, Asia and Latin America [1, 2]. Chronic infection can per-
sist for decades, and may be asymptomatic or cause
gastrointestinal, cardiopulmonary or skin symptoms [3]. In some
individuals with specific types of immune suppression (e.g. exog-
enous corticosteroids and organ transplantation), rapid replica-
tion and dissemination of larvae result in Strongyloides
hyperinfection syndrome (SHS), a condition characterized by
acute severe illness and high mortality (Figure 1) [4].
In 2019, we looked after an Angolan gentleman with
renal transplantation who developed SHS and sadly died [5].
FIGURE 1: Spectrum of human disease caused by S. stercoralis.
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We subsequently reviewed 264 renal transplant recipients at
our centre and found that 30% could be at risk of strongyloides
based on their likely ethnic origin, which we determined using
Onolytics, a software that assigns the most probable origin of
each individual based on first name and surname [6] (Figure 2).
Eosinophilia prior to transplantation was significantly more
common in this group (49% versus 36%; P¼ 0.049), as was en-
teric bacteraemia after transplantation (10% versus 4%;
P¼ 0.046). These could indicate undiagnosed infection. Despite
this, none had been tested. Overall mortality of transplant
recipients was low (6% after a median follow-up duration of
4.5 years) and was not associated with country of origin.
In the UK, there are no community-level or transplant clinic
data suggesting the prevalence of strongyloidiasis. However, a
recent systematic review of migrants originating from endemic
countries and arriving/living in any non-endemic country found
a pooled S. stercoralis seroprevalence of 12.2% [7]. Office for
National Statistics data showed that 7.4% of individuals living
in the UK were born in Africa, Asia or Latin America [8].
Therefore, somewhere in the region of 0.9% of individuals re-
ceiving renal transplantation in the UK could be seropositive for
strongyloides.
The risk of SHS in seropositive individuals who undergo or-
gan transplantation is not known. A retrospective study in
Brazil identified 46 cases among 15 860 transplant recipients
(0.3%), but most of these had received pre-emptive anthelmintic
treatment [9]. Despite this, international [10] and US [11] trans-
plantation guidelines make pragmatic recommendations for se-
rological screening of potential recipients. An alternative
approach would be routine treatment of at-risk individuals us-
ing ivermectin (a drug that is both safe and effective for chronic
strongyloidiasis) [12]. UK guidelines only recommend testing for
tropical infections in prospective donors [13].
We would urge clinicians to consider strongyloidiasis in re-
nal transplant recipients if they have ever lived in the tropics.
Serological screening (or treatment based on demographic risk
factors alone) may be beneficial and should be considered for
inclusion in transplantation guidelines.
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